Search

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的探讨血清白细胞介素6(IL-6)与红细胞分布宽度(RDW)联合检测对上消化道再出血的预测价值。方法选取284例上消化道出血患者,采用非条件Logistic多因素回归分析影响上消化道再出血的危险因素;采用受试者工作特征(ROC)曲线分析血清IL-6、RDW对上消化道再出血的预测价值。结果 284例患者中90例发生再出血,发生率为31. 69%。再出血组血清IL-6、RDW水平均高于非再出血组(P均<0. 05)。性别、年龄、吸烟、饮酒、凝血酶原时间、是否接受支持治疗、Hb、RBC、HCT、IL-6水平、RDW是影响上消化道再出血的相关危险因素(P均<0. 05);多因素Logistic回归分析显示,年龄≥60岁、凝血酶原时间≥16 s、未接受支持治疗、IL-6水平升高、RDW升高是上消化道发生再出血的独立危险因素(P均<0. 05)。血清IL-6、RDW联合检测的特异度(89. 98%)、灵敏度(86. 62%)、阳性预测值(89. 37%)、阴性预测值(85. 19%)均高于单独指标检测(P均<0. 05)。结论血清IL-6与RDW联合检测对上消化道再出血有较高的预测价值。 [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Oncology is the property of Chinese Journal of Oncology / Zhonghua Zhongliu Zazhi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的观察上消化道出血(UGIH)患者红细胞分布宽度（RDW)变化，并探讨其临床意义。方法收集 UGIH患者200例作为UGIH组、体检健康者90例作为健康对照组。UGIH组人院后均给予对症治疗。根据出血量 将UGIH组分为出血<250 mL 75例、出血250 ~ 400 mL 64例、出血>400 mL 61例。UGIH组于治疗前后，对照组 于体检时检测血常规及RDW。采用Spearman相关分析RDW与血红蛋白（Hb)、红细胞（RBC)、血小板（HCT)的相 关性。结果出血<250 mL的患者Hb、RBC、HCT与健康对照组比较差异无统计学意义（P均>0.05 )，而RDW 值较健康对照组高(P均<0.05);出血250〜400 mL、出血>400 mL的患者Hb、RBC、HCT及RDW值与健康对照 组比较差异有统计学意义(P均<0.05)。治疗前UGIH组Hb、RBC、HCT较健康对照组低，RDW值较健康对照组 高(P均<0.05)。与治疗前比较，治疗第4、7天UGIH组Hb、RBC、HCT升高（P均< 0• 05)，RDW值降低（P均< 0.05)，至治疗第7天以上指标基本恢复正常。RDW与Hb、RBC、HCT均呈负相关r分别为-0. 659、-0.571、 -0.498，P均<0.05)。结论 UGIH患者RDW值升高，且RDW变化可反映患者出血量及病情转归。 [ABSTRACT FROM AUTHOR]

目的：观察宫颈癌组织Krüppel样转录因子4（ KLF4）表达变化，并探讨其意义。方法选择宫颈癌标本121例份、慢性宫颈炎组织标本35例份、正常宫颈组织标本35例份。采用组织微阵列和免疫组织化学法检测以上组织中的KLF4、Ki-67，通过电话及门诊复查的方式对宫颈癌患者进行随访，记录患者无病生存期（ PFS）、总生存期（ OS）。采用Spearman秩相关分析宫颈癌组织中KLF4与Ki-67表达的关系；用Cox比例风险模型分析OS、PFS与KLF4阳性表达的关系。结果宫颈癌组织、慢性宫颈炎组织、正常宫颈组织中KLF4阳性表达率分别为26．44％、80．00％、91．43％，宫颈癌组织与慢性宫颈炎组织、正常宫颈组织比较，P均＜0．05。宫颈癌组织中KLF4阳性表达率与Ki-67阳性表达率呈负相关（rs ＝－0．284，P＜0．05）。宫颈癌病理分级越差，KLF4阳性表达率越低（P＜0．05）；宫颈癌临床分期越高，KLF4阳性表达率越低（P＜0．05）。 Cox比例风险模型分析发现，患者的OS、PFS与KLF4阳性表达有关（HR分别为0．682、0．521，P均＜0．05）。结论宫颈癌组织中KLF4低表达，与Ki-67表达呈负相关，阳性表达率越高预后越好。 [ABSTRACT FROM AUTHOR]